HUP0401123A2 - Galantamin alkalmazása a központi idegrendszer kóros tüneteinek kezelésére pszichotróp anyagokkal történő mérgezés esetén - Google Patents
Galantamin alkalmazása a központi idegrendszer kóros tüneteinek kezelésére pszichotróp anyagokkal történő mérgezés eseténInfo
- Publication number
- HUP0401123A2 HUP0401123A2 HU0401123A HUP0401123A HUP0401123A2 HU P0401123 A2 HUP0401123 A2 HU P0401123A2 HU 0401123 A HU0401123 A HU 0401123A HU P0401123 A HUP0401123 A HU P0401123A HU P0401123 A2 HUP0401123 A2 HU P0401123A2
- Authority
- HU
- Hungary
- Prior art keywords
- psychotropic
- treatment
- substances
- nervous system
- central nervous
- Prior art date
Links
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 title abstract 4
- 230000000506 psychotropic effect Effects 0.000 title abstract 4
- 239000000126 substance Substances 0.000 title abstract 3
- 210000003169 central nervous system Anatomy 0.000 title abstract 2
- 229960003980 galantamine Drugs 0.000 title abstract 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 title abstract 2
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 title 1
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 title 1
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 title 1
- 230000035987 intoxication Effects 0.000 title 1
- 231100000566 intoxication Toxicity 0.000 title 1
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 title 1
- 230000007170 pathology Effects 0.000 title 1
- 229940079593 drug Drugs 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 231100000614 poison Toxicity 0.000 abstract 3
- 239000003440 toxic substance Substances 0.000 abstract 3
- 230000001684 chronic effect Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000002035 prolonged effect Effects 0.000 abstract 2
- 206010037180 Psychiatric symptoms Diseases 0.000 abstract 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 231100001133 acute intoxication condition Toxicity 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
A találmány galantamin alkalmazására irányul, szabad bázisként vagysavaddíciós sóként agyi, központi idegrendszeri vagy pszichiátriaitünetek, működésképtelenségi tünetek vagy zavarok kezelésére; amelyekpszichotróp anyagok felvétele során fordulnak elő, a függőséget okozóanyagokkal, mérgező anyagokkkal vagy gyógyszerekkel történőesetenkénti vagy krónikus visszaélés következményeként; vagymellékhatásként gyógyszerek rendeltetés szerinti; különösen ismételtvagy meghosszabbított alkalmazás esetén; vagy gyógyszerek nemrendeltetés szerinti felhasználásának hatásaként, különösen ismételtvagy meghosszabbított alkalmazás esetén; vagy pszichotróp toxikusanyagok okozta akut mérgezés eredményeként; vagy pszichotróp hatásúmérgező anyagok krónikus hatásának eredményeként emberek vagy másgerincesek esetében. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10119862A DE10119862A1 (de) | 2001-04-24 | 2001-04-24 | Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen |
| PCT/EP2002/004277 WO2002085370A1 (de) | 2001-04-24 | 2002-04-18 | Verwendung von galanthamin zur behandlung von krankheitserscheinungen des zentralen nervensystems aufgrund von intoxikationen mit psychotropen substanzen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0401123A2 true HUP0401123A2 (hu) | 2004-09-28 |
| HUP0401123A3 HUP0401123A3 (en) | 2008-01-28 |
Family
ID=7682409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0401123A HUP0401123A3 (en) | 2001-04-24 | 2002-04-18 | Utilization of galanthamine for the treatment of pathologies of the central nervous system owing to intoxications with psychotropic substances |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8207159B2 (hu) |
| EP (1) | EP1383507B1 (hu) |
| JP (1) | JP2004531533A (hu) |
| KR (1) | KR20040005934A (hu) |
| CN (1) | CN100400043C (hu) |
| AR (1) | AR033468A1 (hu) |
| AT (1) | ATE378052T1 (hu) |
| AU (1) | AU2002308148B2 (hu) |
| BR (1) | BR0209126A (hu) |
| CA (1) | CA2444818C (hu) |
| CZ (1) | CZ20032789A3 (hu) |
| DE (2) | DE10119862A1 (hu) |
| DK (1) | DK1383507T3 (hu) |
| EA (1) | EA200301135A1 (hu) |
| ES (1) | ES2296990T3 (hu) |
| HK (1) | HK1062401A1 (hu) |
| HU (1) | HUP0401123A3 (hu) |
| IL (2) | IL158382A0 (hu) |
| MX (1) | MXPA03009765A (hu) |
| NO (1) | NO20034740L (hu) |
| NZ (1) | NZ529004A (hu) |
| PL (1) | PL207525B1 (hu) |
| PT (1) | PT1383507E (hu) |
| SK (1) | SK287235B6 (hu) |
| TW (1) | TWI329512B (hu) |
| WO (1) | WO2002085370A1 (hu) |
| ZA (1) | ZA200308004B (hu) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004216360B2 (en) * | 2003-02-27 | 2009-09-17 | Eisai R & D Management Co., Ltd. | Pharmaceutical composition for treatment of drug dependence |
| DE10338544B4 (de) * | 2003-08-19 | 2017-08-31 | Janssen Pharmaceutica N.V. | Buccale Formulierungen des Galanthamins und deren Anwendungen |
| FR2930891B1 (fr) | 2008-05-06 | 2010-09-24 | Biocodex | Composes anti-amnesiants et compositions pharmaceutiques les comprenant |
| EP2586436A1 (en) | 2011-10-31 | 2013-05-01 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor |
| US20180200259A1 (en) * | 2015-05-18 | 2018-07-19 | Synaptec Development Llc | GALANTAMINE CLEARANCE OF AMYLOID ß |
| US20230202978A1 (en) | 2022-03-04 | 2023-06-29 | Reset Pharmaceuticals, Inc. | Co-crystal or salt |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1193061B (de) | 1961-12-20 | 1965-05-20 | Vni Chimiko Pharmazewtitschesk | Verfahren zur Gewinnung von Galanthamin-hydrobromid aus Pflanzen der Familie der Amaryllidaceen |
| US3797494A (en) | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
| US3742951A (en) | 1971-08-09 | 1973-07-03 | Alza Corp | Bandage for controlled release of vasodilators |
| US3996934A (en) | 1971-08-09 | 1976-12-14 | Alza Corporation | Medical bandage |
| US4031894A (en) | 1975-12-08 | 1977-06-28 | Alza Corporation | Bandage for transdermally administering scopolamine to prevent nausea |
| DE3315272C2 (de) | 1983-04-27 | 1986-03-27 | Lohmann Gmbh & Co Kg, 5450 Neuwied | Pharmazeutisches Produkt und Verfahren zu seiner Herstellung |
| US4666829A (en) * | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
| US6150354A (en) * | 1987-01-15 | 2000-11-21 | Bonnie Davis | Compounds for the treatment of Alzheimer's disease |
| DE3843239C1 (hu) | 1988-12-22 | 1990-02-22 | Lohmann Therapie Syst Lts | |
| US5015645A (en) * | 1989-10-19 | 1991-05-14 | Ciba-Geigy Corporation | Tetracyclic pyrrole lactam derivatives |
| DE4010079A1 (de) * | 1990-03-29 | 1991-10-02 | Lohmann Therapie Syst Lts | Pharmazeutische formulierung zur behandlung des alkoholismus |
| US5519017A (en) * | 1990-03-29 | 1996-05-21 | Lts Lohmann Therapie-Systeme Gmbh + Co. Kg | Pharmaceutic formulation for the treatment of alcoholism |
| US5336675A (en) * | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
| DE4301782C1 (de) * | 1993-01-23 | 1994-08-25 | Lohmann Therapie Syst Lts | Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit |
| DE19509663A1 (de) | 1995-03-17 | 1996-09-19 | Lohmann Therapie Syst Lts | Verfahren zur Isolierung von Galanthamin |
| US5965571A (en) * | 1996-08-22 | 1999-10-12 | New York University | Cholinesterase inhibitors for treatment of Parkinson's disease |
| US5932557A (en) * | 1997-08-12 | 1999-08-03 | Mustafa; S. Jamal | Adenosine A1 receptor antisense oligonucleotide treatment of alcohol and marijuana-induced psychomotor impairments |
| CN1240384C (zh) * | 1999-11-04 | 2006-02-08 | 美国爱科赛尔制药有限公司 | 石杉碱经皮给药制剂 |
| US20020151591A1 (en) * | 2000-10-17 | 2002-10-17 | Anabella Villalobos | Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders |
-
2001
- 2001-04-24 DE DE10119862A patent/DE10119862A1/de not_active Withdrawn
-
2002
- 2002-04-18 AT AT02764017T patent/ATE378052T1/de active
- 2002-04-18 SK SK1315-2003A patent/SK287235B6/sk not_active IP Right Cessation
- 2002-04-18 US US10/475,357 patent/US8207159B2/en not_active Expired - Fee Related
- 2002-04-18 WO PCT/EP2002/004277 patent/WO2002085370A1/de active IP Right Grant
- 2002-04-18 CN CNB028088905A patent/CN100400043C/zh not_active Expired - Lifetime
- 2002-04-18 MX MXPA03009765A patent/MXPA03009765A/es active IP Right Grant
- 2002-04-18 PT PT02764017T patent/PT1383507E/pt unknown
- 2002-04-18 JP JP2002582943A patent/JP2004531533A/ja active Pending
- 2002-04-18 ES ES02764017T patent/ES2296990T3/es not_active Expired - Lifetime
- 2002-04-18 EA EA200301135A patent/EA200301135A1/ru unknown
- 2002-04-18 IL IL15838202A patent/IL158382A0/xx unknown
- 2002-04-18 DE DE50211207T patent/DE50211207D1/de not_active Expired - Lifetime
- 2002-04-18 BR BR0209126-7A patent/BR0209126A/pt not_active Application Discontinuation
- 2002-04-18 NZ NZ529004A patent/NZ529004A/en unknown
- 2002-04-18 CA CA002444818A patent/CA2444818C/en not_active Expired - Lifetime
- 2002-04-18 DK DK02764017T patent/DK1383507T3/da active
- 2002-04-18 PL PL366840A patent/PL207525B1/pl not_active IP Right Cessation
- 2002-04-18 CZ CZ20032789A patent/CZ20032789A3/cs unknown
- 2002-04-18 EP EP02764017A patent/EP1383507B1/de not_active Expired - Lifetime
- 2002-04-18 HU HU0401123A patent/HUP0401123A3/hu unknown
- 2002-04-18 AU AU2002308148A patent/AU2002308148B2/en not_active Ceased
- 2002-04-18 KR KR10-2003-7013971A patent/KR20040005934A/ko active Search and Examination
- 2002-04-22 TW TW091108204A patent/TWI329512B/zh not_active IP Right Cessation
- 2002-04-24 AR ARP020101482A patent/AR033468A1/es unknown
-
2003
- 2003-10-13 IL IL158382A patent/IL158382A/en active IP Right Grant
- 2003-10-15 ZA ZA200308004A patent/ZA200308004B/en unknown
- 2003-10-23 NO NO20034740A patent/NO20034740L/no not_active Application Discontinuation
-
2004
- 2004-07-02 HK HK04104742A patent/HK1062401A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20090058A2 (en) | Prodrugs of excitatory amino acids | |
| EP1900362A3 (en) | Alfa-aminoamide derivatives useful in the treatment of addictive disorders | |
| GEP20084325B (en) | Purine compounds and uses thereof as cannabinoid receptor ligandspurine compounds and uses thereof as cannabinoid receptor ligands | |
| CY1105082T1 (el) | Χρηση της φλιβανσepινης στην αγωγη διαταραχων της σεξουαλικης επιθυμιας | |
| EA200700909A1 (ru) | Азаиндолкарбоксамиды | |
| WO2007127505A3 (en) | Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system | |
| TNSN06053A1 (en) | 6-substituted anilino purines as rtk inhibitors | |
| GT200100183A (es) | Derivados de quinolina y quinazolina. | |
| BRPI0508434A (pt) | usos de 1-aminociclohexano para o tratamento de distúrbios comportamentais associados ao mal de alzheimer | |
| CY1110391T1 (el) | Αρυλβινυλαζακυκλοαλκανια και μεθοδοι παρασκευης και χρησεως τους | |
| NO20015413L (no) | Anvendelse av dopamin-D3-reseptor-ligander for fremstilling av medikamenter for behandling av nyrefunksjonsforstyrrelser | |
| SE0401465D0 (sv) | New substituted piperdines as modulators of dopamine neurotransmission | |
| EA200970817A1 (ru) | Лекарственная форма, содержащая 1{6-[(3-циклобутил-2,3,4,5-тетрагидро-1н-3-бензазепин-7-ил)окси]-3-пиридинил}-2-пирролидинон или его соль и стабилизатор, который уменьшает его деградацию | |
| HUP0401123A2 (hu) | Galantamin alkalmazása a központi idegrendszer kóros tüneteinek kezelésére pszichotróp anyagokkal történő mérgezés esetén | |
| ATE439363T1 (de) | Imidazo 2,1-b -1,3,4-thiadiazole sulfonamides | |
| DK2091942T3 (da) | Substituerede pyrazinderivater til anvendelse som en medicin | |
| EA200700707A1 (ru) | Производные 2-ациламинотиазола | |
| MY135676A (en) | Use of deoxypeganine for the treatment of pathological manifestations of the central nervous system based on intoxication with psychotropic substances | |
| DK1732648T3 (da) | Sygdomsbehandling | |
| NO20084819L (no) | Substituerte pyrazinonderivater for anvendelse som en medisin | |
| WO2007053352A3 (en) | Pyrroloquinolinone derivatives as 5-hydroxytryptamine-6 ligands | |
| DE602004020337D1 (de) | Anticholinergika enthaltende Arzneimittel zur Behandlung von Krankheiten der ableitenden Harnwege | |
| WO2005097138A3 (en) | Combinations comprising oxcarbazepine to treat affective disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |